IP Library › Granted Patent US 12,322,515
Granted Patent B2
US 12,322,515 · App. 18/353,737 · Granted Jun 3, 2025

Personalized wellness systems and methods of use

Inventors: James Crouch (Boulder, CO); Sean Callan (Denver, CO)
Assignee: Onikoroshi, LLC
G16H50/30G16B20/00G16B40/00G16H10/40G16H10/60G16H20/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,322,515
App. No.
18/353,737
Granted
Jun 3, 2025
Kind
B2
Abstract

A health and wellness system for a non-human subject comprising analyzing genetic data and phenotypic data of the non-human subject with a machine learning algorithm and making a recommendation or recommendation for products or activities for the non-human subject.

Claims (77)

1. A method for identifying a nutritional product recommended for a non-human animal subject, the method comprising:

(a) receiving genetic data at a plurality of genomic loci of the non-human animal subject, wherein at least one genomic locus of the plurality of genomic loci is associated with a first condition, wherein the first condition is not a breed type;

(b) receiving phenotypic data pertaining to a plurality of phenotypes of the non-human animal subject, wherein at least one phenotype of the plurality of phenotypes is associated with a second condition;

(c) producing a genotype-phenotype profile for the non-human animal subject by processing a data set comprising the genetic data and the phenotypic data to determine qualitative or quantitative measures of the at least one genomic locus of the plurality of genomic loci, and qualitative or quantitative measures of the at least one phenotype of the plurality of phenotypes;

(d) applying a machine learning prediction model to the genotype-phenotype profile of the non-human animal subject to identify the nutritional product recommended for the non-human subject, based at least in part, on a likelihood that the non-human animal subject has:

(i) the first condition or a risk of developing the first condition; and

(ii) the second condition or a risk of developing the second condition;

(e) ranking the first condition and the second condition based, at least in part, on severity of the first condition and the second condition to identify a highest ranking condition of the first condition and the second condition; and

(f) administering the nutritional product to the non-human animal subject, wherein the nutritional product:

(i) comprises a food; and

(ii) improves, ameliorates, or prevents at least the highest ranking condition or the risk of developing at least the highest ranking condition in the non-human animal subject.

2. The method of claim 1 , wherein the first condition or the second condition comprises one or more genetic conditions, one or more nutritional conditions, one or more clinical conditions, one or more fitness conditions, one or more dermatological conditions, one or more allergy conditions, or any combination thereof.

3. The method of claim 1 , wherein the non-human animal subject is a feline, a canine, or a farm animal.

4. The method of claim 3 , wherein the non-human animal subject is a companion animal.

5. The method of claim 1 , wherein the genetic data is determined by:

(i) obtaining or having obtained a biological sample from the non-human animal subject; and

(ii) performing or having performed a genotyping assay on the biological sample.

6. The method of claim 1 , further comprising receiving the genetic data from a nucleic acid sequencing device, wherein the nucleic acid sequencing device comprises a whole genome sequencer, a skim sequencer, a quantitative PCR (qPCR) device, or a DNA microarray.

7. The method of claim 1 , wherein the at least one genomic locus comprises one or more polymorphisms associated with the first condition.

8. The method of claim 1 , further comprising receiving the phenotypic data from a guardian of the non-human animal subject, a veterinarian of the non-human animal subject, or a combination thereof.

9. The method of claim 1 , wherein the plurality of phenotypes comprises any combination of weight, body mass index, sex, age, or breed of the non-human animal subject.

10. The method of claim 1 , further comprising:

receiving activity data of the non-human animal subject;

updating the genotype-phenotype profile with the activity data to produce an updated profile; and

applying the machine learning prediction model to the updated profile.

11. The method of claim 10 , wherein the activity data comprises activity level, activity type, calories burned, time asleep, or any combination thereof.

12. The method of claim 10 , wherein the activity data comprises information obtained from an activity tracking device.

13. The method of claim 1 , further comprising:

receiving environmental data of the non-human animal subject;

updating the genotype-phenotype profile with the environmental data to produce an updated profile; and

applying the machine learning prediction model to the updated profile.

14. The method of claim 13 , wherein the environmental data comprise a city environment, a rural environment, geographic location of residence, presence of allergens, time spent inside/outside, frequency of stair use, or any combination thereof.

15. The method of claim 1 , further comprising:

receiving biomarker data for the non-human animal subject, wherein the biomarker data comprises a presence or a level of one or more biomarkers detected in a biological sample obtained from the non-human animal subject, wherein the one or more biomarkers comprises a protein, a sugar, a lipid, a hormone, a vitamin, a cell, a metabolite, an electrolyte, a mineral, or any combination thereof;

updating the genotype-phenotype profile with the biomarker data to produce an updated profile; and

applying the machine learning prediction model to the updated profile.

16. The method of claim 1 , wherein the machine learning prediction model comprises a clustering algorithm, a decision tree algorithm, a statistical algorithm, gradient boosted machine (GBM), or any combination thereof.

17. The method of claim 16 , wherein the clustering algorithm is a centroid-based clustering algorithm.

18. The method of claim 16 , wherein the machine learning prediction model is a genomic best linear unbiased prediction (GBLUP) or a Bayesian variable selection model.

19. The method of claim 1 , further comprising validating the machine learning prediction model using samples from a validation cohort of non-human animal subjects of the same species that have the first condition or the second condition.

20. The method of claim 1 , further comprising training the machine learning prediction model using samples from a training cohort of non-human animal subjects of the same species.

21. The method of claim 20 , wherein the training data set comprises:

(i) genetic data at a plurality of genomic loci of the training cohort, wherein at least one genomic locus of the plurality of genomic loci is associated with the first condition; and

(ii) phenotypic data pertaining to a plurality of phenotypes of the training cohort of non-human animal subjects, wherein at least one phenotype of the plurality of phenotypes is associated with the second condition.

22. The method of claim 1 , further comprising providing a notification to a guardian of the non-human animal subject or a veterinarian of the non-human animal subject, wherein the notification comprises:

(i) the first condition or a risk of developing the first condition and the second condition or the risk of developing the second condition in the non-human animal subject;

(ii) the genotype-phenotype profile of the non-human animal subject;

(iii) the nutritional product recommended for a non-human animal subject;

(iv) a recommendation for a behavioral modification for the non-human animal subject;

(v) a prescription of a therapeutic or prophylactic intervention for the non-human animal subject; or

(vi) any combination of (i) to (v).

23. The method of claim 22 , wherein the behavioral modification comprises increasing, reducing, or avoiding one or more activities, wherein the one or more activities (i) increases or decreases the risk that the non-human animal subject will develop the first condition or the second condition, or (ii) worsens or improves the first condition or the second condition in the non-human animal subject.

24. The method of claim 23 , wherein the one or more activities comprises:

(i) performance of a physical exercise;

(ii) ingestion of a type or quantity of the nutritional product, wherein the nutritional product further comprises feed, a supplement, a treat, or both;

(iii) exposure to a product;

(iv) usage of the product; or

(v) any combination of (i) to (iv).

25. The method of claim 1 , further comprising:

performing (a) to (b) at a plurality of time points to obtain new genotype data or new phenotype data;

updating the genotype-phenotype profile with the new genotype data, the new phenotype data, or a combination thereof, at the plurality of time points to produce an updated profile; and

applying the machine learning prediction model to the updated profile.

26. The method of claim 25 , further comprising providing a notification to a guardian of the non-human animal subject or a veterinarian of the non-human animal subject at one or more of the plurality of time points, wherein the notification comprises:

(i) the first condition or the risk of developing the first condition and the second condition or the risk of developing the second condition in the non-human animal subject;

(ii) the updated profile of the non-human animal subject;

(iii) a recommendation for a product, a behavioral modification, or any combination thereof, for the non-human animal subject;

(iv) a prescription of a therapeutic or prophylactic intervention for the non-human animal subject; or

(v) any combination of (i) to (iv).

27. The method of claim 1 , further comprising:

receiving biomarker data, activity data, environment data, behavioral data, or clinical data for the non-human animal subject;

producing an updated genotype-phenotype profile for the non-human animal subject by processing the biomarker data, the activity data, the environment data, the behavioral data, or the clinical data, or the combination thereof, to determine quantitative or qualitative measures thereof; and

applying the machine learning prediction model to the updated genotype-phenotype profile of the non-human animal subject to identify:

a new nutritional product or a new amount of the nutritional product recommended for the non-human animal subject; or

a behavioral modification for the non-human animal subject.

28. The method of claim 27 , wherein the clinical data comprises medical history of the non-human animal subject or medical history of a biological relative of the non-human animal subject.

29. The method of claim 27 , wherein the behavioral data comprises chewing, itching, aggression, neurosis, anxiety, energy level, or any combination thereof.

30. The method of claim 1 , wherein the nutritional product further comprises a food, supplement, treat, or both.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2023
From: CROUCH, JAMES; CALLAN, SEAN
To: ONIKOROSHI, LLC
Reel/Frame 064540/0641 →
Continuity (2)
Provisional Application 63513589 · Jul 14, 2023
Related Publication 20250022602A1 · Jan 16, 2025
References Cited (105)
US 6287254B1 · Dodds · 2001 [cited by applicant]
US 6358546B1 · Bebiak et al. · 2002 [cited by applicant]
US 6493641B1 · Singh et al. · 2002 [cited by applicant]
US 6537213B2 · Dodds · 2003 [cited by applicant]
US 6730023B1 · Dodds · 2004 [cited by applicant]
US 7029441B2 · Dodds · 2006 [cited by applicant]
US 7134995B2 · Dodds · 2006 [cited by applicant]
US 7548839B2 · Dodds · 2009 [cited by applicant]
US 7552039B2 · Dodds · 2009 [cited by applicant]
US 7797145B2 · Dodds · 2010 [cited by applicant]
US 7865343B2 · Dodds · 2011 [cited by applicant]
US 7873482B2 · Stefanon et al. · 2011 [cited by applicant]
US 7970552B1 · Stefanon et al. · 2011 [cited by applicant]
US 8060354B2 · Dodds · 2011 [cited by applicant]
US 8234099B2 · Dodds · 2012 [cited by applicant]
US 9242765B2 · Oziomek et al. · 2016 [cited by applicant]
US 9420809B2 · Donavon et al. · 2016 [cited by applicant]
US 10468141B1 · Valenzuela et al. · 2019 [cited by applicant]
US 11501851B2 · Sams et al. · 2022 [cited by applicant]
US 20020022772A1 · Dodds · 2002 [cited by applicant]
US 20030004655A1 · Singh et al. · 2003 [cited by applicant]
US 20040131658A1 · Kaput · 2004 [cited by applicant]
US 20050065736A1 · Bauck et al. · 2005 [cited by applicant]
US 20050090718A1 · Dodds · 2005 [cited by applicant]
US 20050158734A1 · Kaput · 2005 [cited by applicant]
US 20060045909A1 · Friesen et al. · 2006 [cited by applicant]
US 20060200320A1 · Al-Murrani · 2006 [cited by applicant]
US 20060235625A1 · Ostrander et al. · 2006 [cited by applicant]
US 20070118295A1 · Al-Murrani · 2007 [cited by applicant]
US 20100304396A1 · Dodds · 2010 [cited by applicant]
US 20110153221A1 · Stefanon et al. · 2011 [cited by applicant]
US 20110246405A1 · Dodds · 2011 [cited by applicant]
US 20120185175A1 · Dodds · 2012 [cited by applicant]
US 20120303286A1 · Dodds · 2012 [cited by examiner]
US 20120309639A1 · Hakonarson · 2012 [cited by examiner]
US 20140141131A1 · Oziomek et al. · 2014 [cited by applicant]
US 20140141134A1 · Johnson et al. · 2014 [cited by applicant]
US 20140272028A1 · Donavon et al. · 2014 [cited by applicant]
US 20150072048A1 · Potthoff et al. · 2015 [cited by applicant]
US 20150242566A1 · Samer · 2015 [cited by applicant]
US 20150286774A1 · Lohi et al. · 2015 [cited by applicant]
US 20160364522A1 · Frey · 2016 [cited by examiner]
US 20170220734A1 · Colavin · 2017 [cited by examiner]
US 20180328945A1 · Nova et al. · 2018 [cited by applicant]
US 20190295691A1 · Garshon · 2019 [cited by examiner]
US 20210287758A1 · Wong et al. · 2021 [cited by applicant]
US 20230061512A1 · Sams et al. · 2023 [cited by applicant]
US 20230106107A1 · Boyko · 2023 [cited by examiner]
US 20230157320A1 · Roche et al. · 2023 [cited by applicant]
EP 4062411A1 · 2022 [cited by applicant]
EP 4127224A1 · 2023 [cited by applicant]
WO WO2020109858A1 · 2020 [cited by applicant]
WO WO2021101896A1 · 2021 [cited by applicant]
WO WO2021202910A1 · 2021 [cited by applicant]
WO WO2021207370A1 · 2021 [cited by applicant]
Gjuvsland et al. “Bridging the Genotype-Phenotype Gap: What does it Take?” J. Physiol (2013) vol. 591, No. 8, pp. 2055-2066 (Year: 2013). [cited by examiner]
AAFCO, PFC Committee Report/Minutes AAFCO Annual Meeting Aug. 4, 2015; Denver, CO. (2015). Available at https://www.aafco.org/wp-content/uploads/2023/01/Pet_Food_Report_2015_Annual.pdf. [cited by applicant]
Ahner et al., Protein biomarkers in serum and urine for determining presence or absence of hip dysplasia in a canine model. J Orthop Res. 37(4):916-920 (2019). [cited by applicant]
Almela et al., Selected serum oxidative stress biomarkers in dogs with non-food-induced and food-induced atopic dermatitis. Vet Dermatol. 29(3):229-e82 (2018). [cited by applicant]
Asahina et al., Serum canine thymus and activation-regulated chemokine (TARC/CCL17) concentrations correlate with disease severity and therapeutic responses in dogs with atopic dermatitis. Vet Dermatol. 31(6):446-455 (2… [cited by applicant]
Axelsson et al., The genomic signature of dog domestication reveals adaptation to a starch-rich diet. Nature. 495(7441):360-364 (2013). [cited by applicant]
Basepaws Veterinary, Basepaws canine baseline genetic tests. Basepaws Veterinary by Zoetis. (2022). Available at https://basepawsvet.com/canine-products. [cited by applicant]
Basepaws Veterinary, Basepaws feline genetic & oral microbiome tests. Basepaws Veterinary by Zoetis. (2022). Available at https://basepawsvet.com/feline-products. [cited by applicant]
Bergström et al., Origins and genetic legacy of prehistoric dogs. Science. 370(6516):557-564 (2020). [cited by applicant]
Biber Ingenity: 877-Igenity. Bieber Red Angus Ranch. (2018). Available at https://bieberredangus.com/igenity/. [cited by applicant]
Cardona-Ramírez et al., The differentiating ability of four plasma biomarkers in canine hip dysplasia. Vet Clin Pathol. 48(2):320-327 (2019). [cited by applicant]
Carlos et al., Canine metabolomics advances. Metabolomics. 16(2):16 (2020). [cited by applicant]
Chon et al., Genomic tumor analysis provides clinical guidance for the management of diagnostically challenging cancers in dogs. J Am Vet Med Assoc. 261(5):668-677 (2023). [cited by applicant]
Donner et al., Genetic prevalence and clinical relevance of canine Mendelian disease variants in over one million dogs. PLoS Genet. 19(2):e1010651 (2023). [cited by applicant]
Embark, Better care for your patients is in their DNA. (2022). Available at https://embarkvet.com/vets/. [cited by applicant]
Forcada et al., A genome-wide association study identifies novel candidate genes for susceptibility to diabetes mellitus in non-obese cats. PLoS One. 16(12):e0259939 (2021). [cited by applicant]
González-Arostegui et al., Changes in biomarkers of redox status in serum and saliva of dogs with hypothyroidism. BMC Vet Res. 9(1):33 (2023). [cited by applicant]
González-Arostegui et al., Changes in the salivary metabolome in canine hypothyroidism: A pilot study. Res Vet Sci. 151:189-195 (2022). [cited by applicant]
Heishima et al., Circulating microRNA-214 and -126 as potential biomarkers for canine neoplastic disease. Sci Rep. 7(1):2301 (2017). [cited by applicant]
Hokamp et al., Renal biomarkers in domestic species. Vet Clin Pathol. 45(1):28-56 (2016). [cited by applicant]
Iams, Iams™M Pet Food + Wisdom Panel™ DNA test for Cats & Dogs (2023). Available at https://www.iams.com/wisdom-panel. [cited by applicant]
Jones, Best dog DNA tests 2023: DNA My Dog vs Wisdom Panel vs Embark vs Orivet vs EasyDNA & More. Canine Journal. May 23, 2023. [cited by applicant]
Koury et al., Phosphodiesterase 4D, miR-203 and selected cytokines in the peripheral blood are associated with canine atopic dermatitis. PLoS One. 14(6):e0218670 (2019). [cited by applicant]
Lindblad-Toh et al., Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature. 438(7069):803-819 (2005). [cited by applicant]
Marsella, Advances in our understanding of canine atopic dermatitis. Vet Dermatol. 32(6):547-e151 (2021). [cited by applicant]
Martins et al., Clinical-pathological and immunological biomarkers in dogs with atopic dermatitis. Vet Immunol Immunopathol. 205:58-64 (2018). [cited by applicant]
Mazaki-Tovi et al., Increased serum leptin and insulin concentrations in canine hypothyroidism. Vet J. 183(1):109-114 (2010). [cited by applicant]
Meddens et al., Genomic analysis of diet composition finds novel loci and associations with health and lifestyle. Mol Psychiatry. 26(6):2056-2069 (2021). [cited by applicant]
Muñoz-Prieto et al., Untargeted metabolomic profiling of serum in dogs with hypothyroidism. Res Vet Sci. 136:6-10 (2021). [cited by applicant]
Neogen, Igenity® Beef: Item No. 44—Brochure and Technical Specification sheet. (2023). Available at https://www.neogen.com/categories/igenity-profiles/igenity-beef/?min=GS_SL_44. [cited by applicant]
Neogen, Igenity® Canine Wellness. (2020). Available at https://www.neogen.com/igenity-canine-wellness/. [cited by applicant]
O'Kell et a., Untargeted metabolomic analysis in naturally occurring canine diabetes mellitus identifies similarities to human Type 1 Diabetes. Sci Rep. 7(1):9467 (2017). [cited by applicant]
O'Kell et al., Untargeted metabolomic analysis in non-fasted diabetic dogs by UHPLC-HRMS. Metabolomics. 15(2):15 (2019). [cited by applicant]
Pallotti et al., Dog-human translational genomics: state of the art and genomic resources. J Appl Genet. 63(4):703-716 (2022). [cited by applicant]
Pet Business, Iams, Wisdom Panel Partner on Genetics-Based Nutrition. Pet Business Digital mag, 2pgs. May 2023. Available at https://digitalmag.petbusiness.com/petbusiness/library/item/may_2023/4102425/. [cited by applicant]
Petdx, Early Cancer Detection in Dogs with a Simple Blood Draw. (2023). Available at https://petdx.com/. [cited by applicant]
Piras et al., Identification of genetic susceptibility factors associated with canine gastric dilatation-volvulus. Genes (Basel). 11(11):1313 (2020). [cited by applicant]
Plassais et al., Analysis of large versus small dogs reveals three genes on the canine X chromosome associated with body weight, muscling and back fat thickness. PLoS Genet. 13(3):e1006661 (2017). [cited by applicant]
Royal Canin, Discover the secrets of your dog's DNA-Genetic Health Analysis. (2023) Available at https://www.royalcanin.com/us/dogs/genetic-health-analysis. [cited by applicant]
Ryad et al., Oxidative biomarkers and lipid alterations in euthyroid and hypothyroid dogs. Comp Clin Pathol. 30:571-576 (2021). [cited by applicant]
Santoro et al., Evaluation of cutaneous and circulating (serum and exosomes) levels of chemokines (CCL17, CCL22, CCL27 and CCL28) in atopic dogs and their correlation with severity of the disease. Vet Dermatol. 33(3):19… [cited by applicant]
Vidium, SearchLight DNA™ for veterinarians. (2023). Available at https://vidiumah.com/searchlight-dna/. [cited by applicant]
Wang et al.; Genome-wide association studies for canine hip dysplasia in single and multiple populations—implications and potential novel risk loci. BMC Genomics. 22(1):636 (2021). [cited by applicant]
Williams et al., Body Condition Scores. VCA Animal Hospital. (2023). Available at https://vcahospitals.com/know-your-pet/body-condition-scores. [cited by applicant]
Winiarczyk et al., Proteomic analysis of tear film obtained from diabetic dogs. Animals. 10(12):2416 (2020). [cited by applicant]
Wisdompanel, Royal Canin® Genetic Health Analysis™: disease and mutation tests. Available at https://wisdompanel.my.salesforce-sites.com/royalcaningha/, (2021). [cited by applicant]
Wood et al., Genome-wide association analysis of canine atopic dermatitis and identification of disease related SNPs. Immunogenetics. 61(11-12):765-772 (2009). [cited by applicant]
Zelezniak et al., Machine learning predicts the yeast metabolome from the quantitative proteome of kinase knockouts. Cell Syst. 7(3): 269-283.e6 (2018). [cited by applicant]
McConnel, Blair. For the Future of Pet Care Genomics, Look to Livestock. Linkedin. Available at https://www.linkedin.com/pulse/future-pet-care-genomics-look-livestock-blair-mcconnel-dukce/?trackingId=VAHXLpRfYpw327ytZEd… [cited by applicant]
PCT/US2024/037714 International Search Report and Written Opinion dated Dec. 11, 2024. [cited by applicant]
Cited By (1)
US 12,488,901